Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Jun Imagawa"'
Autor:
Jun Imagawa, Yoshiaki Chinen, Toru Kiguchi, Chisaki Mizumoto, Katsumichi Fujimaki, Toshihiro Fukushima, Masayuki Mita, Kazunori Murai, Satoshi Wakita, Takayuki Ikezoe, Satoshi Kimura, Chikashi Yoshida, Takaaki Ono, Takeshi Kondo, Atsushi Kawaguchi, Junichi Sakamoto, Ayako Takamori, Jun Aoki, Katsuhiro Io, Kaori Karimata, Yasufumi Matsuda, Kaichi Nishiwaki, Kensuke Usuki, Hirohiko Shibayama, Joji Shimono, Takashi Kumagai, Tomoharu Takeoka, Junya Kuroda, Shinya Kimura, Masatomo Miura, Kensuke Nakao, Yousuke Minami, Nobuhiko Uoshima, Hiroshi Ureshino, Koiti Inokuchi, Hideo Tanaka
Publikováno v:
The Lancet. Haematology. 8(12)
Summary Background BCR-ABL1 tyrosine kinase inhibitors (TKIs) are commonly initiated in older patients with chronic myeloid leukaemia in the chronic phase at standard doses. However, because of their safety profile in this population, appropriate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8e609cd0305848ad101ef873748a2dc
https://pubmed.ncbi.nlm.nih.gov/34826413
https://pubmed.ncbi.nlm.nih.gov/34826413
Autor:
Nobuhiko Uoshima, Masayuki Mita, Chisaki Mizumoto, Hiroshi Ureshino, Satoshi Wakita, Hirohiko Shibayama, Koiti Inokuchi, Satoshi Kimura, Kaori Karimata, Kensuke Nakao, Joji Shimono, Toru Kiguchi, Kaichi Nishiwaki, Hideo Tanaka, Katsumichi Fujimaki, Takayuki Ikezoe, Katsuhiro Io, Takashi Kumagai, Toshihiro Fukushima, Atsushi Kawaguchi, Yoshiaki Chinen, Yasufumi Matsuda, Ayako Takamori, Kazunori Murai, Jun Aoki, Yosuke Minami, Takaaki Ono, Takeshi Kondo, Chikashi Yoshida, Junya Kuroda, Junichi Sakamoto, Tomoharu Takeoka, Shinya Kimura, Masatomo Miura, Kensuke Usuki, Jun Imagawa
Publikováno v:
Blood. 138:3601-3601
Introduction: Tyrosine kinase inhibitors (TKIs) dramatically improved the prognosis of chronic myelogenous leukemia (CML), as nearly half of CML patients presenting with a deep molecular response (DMR) over several years could achieve treatment-free
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c38884d0460be847bad457c47eec50c
https://doi.org/10.1182/blood-2021-149483
https://doi.org/10.1182/blood-2021-149483
Autor:
Jun Imagawa
Publikováno v:
Leukemia & Lymphoma. 59:3013-3015
Acute promyelocytic leukemia (APL) is most commonly accompanied by disseminated intravascular coagulation (DIC), which can cause early death from bleeding. Conventional chemotherapeutic drugs can k...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32fabec0da666cc2a11e2cfa15043607
https://doi.org/10.1080/10428194.2018.1443333
https://doi.org/10.1080/10428194.2018.1443333
Autor:
Yasutaka Kakinoki, Junichi Sakamoto, Reiko Watanabe, Tetsuo Nishimoto, Masayuki Hino, Kazuhiko Ikeda, Tsutomu Sato, Yoji Ishida, Takaaki Hosoki, Tsutomu Kobayashi, Shugo Kowata, Motohiro Shindo, Shinya Kimura, Nobuhiko Uoshima, Toshio Kitawaki, Hiroshi Ureshino, Akifumi Takaori-Kondo, Hideo Tanaka, Masaya Okada, Naoki Takezako, Hirohisa Nakamae, Jun Imagawa, Hirohiko Shibayama, Atsushi Kawaguchi, Kazunori Murai, Takayuki Ikezoe, Masaya Hayakawa, Takashi Kumagai
Publikováno v:
The Lancet. Haematology. 7(3)
Summary Background A previous dasatinib discontinuation (DADI) trial showed that 31 (49%) of 63 patients with chronic-phase chronic myeloid leukaemia who were treated with second-line or subsequent dasatinib could discontinue the drug safely. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e464da453c792f6533b067b4d61903b3
https://pubmed.ncbi.nlm.nih.gov/31978329
https://pubmed.ncbi.nlm.nih.gov/31978329
Autor:
Toshio Kitamura, Jiro Kitaura, Akihiro Ito, Hirotaka Matsui, Hironori Harada, Ye Ding, Norio Komatsu, Naoko Kato, Sayuri Nishikawa, Yoshihiro Hayashi, Yuka Harada, Jun Imagawa, Naoki Shingai, Yuki Kagiyama, Atsushi Iwama, Issay Kitabayashi, Yuki Maemoto, Shintaro Hokaiwado
Publikováno v:
Blood advances. 3(7)
Chronic myelomonocytic leukemia (CMML) constitutes a hematopoietic stem cell (HSC) disorder characterized by prominent monocytosis and myelodysplasia. Although genome sequencing has revealed the CMML mutation profile, the mechanism of disease develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a047ce44755323038616a22f1ecb786a
https://pubmed.ncbi.nlm.nih.gov/30944097
https://pubmed.ncbi.nlm.nih.gov/30944097
Autor:
Daichi Inoue, Hironori Harada, Kiyoshi Ando, Goro Sashida, Hirotaka Matsui, Jun Imagawa, Yuka Harada, Toshio Kitamura, Ye Ding, Noriko Doki, Atsushi Iwama, Hiromichi Matsushita, Takashi Yahata
Publikováno v:
Blood. 121:3434-3446
RUNX1/AML1 mutations have been identified in myelodysplastic syndromes (MDSs). In a mouse bone marrow transplantation model, a RUNX1 mutant, D171N, was shown to collaborate with Evi1 in the development of MDSs; however, this is rare in humans. Using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460df54419d4c77bc1ee097fd24e1f02
https://doi.org/10.1182/blood-2012-06-434423
https://doi.org/10.1182/blood-2012-06-434423
Autor:
Tadashi Yoshino, Tetsumi Yoshida, Jun Imagawa, Akira Sakai, Akiro Kimura, Shinichi Takada, Masaaki Noda
Publikováno v:
Journal of Clinical and Experimental Hematopathology. 51:147-150
In August 2010, a 51-year-old man was transferred to our Hematology & Oncology Department from another hospital with a 1-month history of unknown fever, anasarca, and lymphadenopathy of bilateral neck, bilateral axilla, and bilateral inguen. Chest X-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b63e8813989e7cbda01c64ed09909eef
https://doi.org/10.3960/jslrt.51.147
https://doi.org/10.3960/jslrt.51.147
Autor:
Satoshi Hashino, Hirohito Yamazaki, Kensuke Usuki, Kazuo Tsubaki, Yokiko Ohe, Masato Shikami, Hideo Tanaka, Masaya Okada, Toshihiro Fukushima, Masayuki Hino, Hisashi Sakamaki, S Mizuta, Naokuni Uike, Junichi Sakamoto, Tetsuhiko Nomura, Takahiko Utsumi, Hirohisa Nakamae, Yosuke Minami, Yasuhiro Maeda, Toshimasa Kukita, Jun Imagawa, Takashi Kumagai, Takahiro Okamoto, Satoshi Morita, Hiroshi Akasaka, Yoko Adachi, Masaharu Nohgawa, Satoshi Yoshihara, Toshiki Nataduka, Yukari Shirasugi, Masahiro Ogasawara, Hisashi Wakita, Hiroshi Kosugi, Tomoharu Takeoka, Shinya Kimura, Yoji Ishida, Yasushi Onishi, Kazunori Murai, Tsutomu Sato, Hisashi Fukutani, Sachiko Ando, Seiichi Sato, Hisayuki Yokoyama, Yasunori Nakagawa, Hiroto Sakoda, Kazuteru Ohashi, Hirohiko Shibayama, Nobuhiko Uoshima
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:353-360.e1
Introduction We previously reported an interim analysis of the DADI (dasatinib discontinuation) trial. The results showed that 48% of patients with chronic myeloid leukemia in the chronic phase who maintained a deep molecular response (DMR) for ≥ 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e081aedcd3b2e8aaae79922bed4f899e
https://doi.org/10.1016/j.clml.2018.03.004
https://doi.org/10.1016/j.clml.2018.03.004
Publikováno v:
Blood. 114:5201-5205
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by proliferation of one or more myeloid cell lineages. Some patients exhibit leukemic transformation (LT) by unknown mechanisms, and chemotherapy may incre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6da3ef525645514b6efd8cf79fee0bf0
https://doi.org/10.1182/blood-2009-06-223982
https://doi.org/10.1182/blood-2009-06-223982
Autor:
Yuka Harada, Hironori Harada, Hiromasa Niimi, Y Ding, Toshiya Inaba, Taiichi Kyo, Akiro Kimura, Jun Imagawa
Publikováno v:
Leukemia. 20:635-644
AML1/RUNX1 mutations have been reported frequently in myelodysplastic syndrome (MDS) patients, especially those diagnosed with refractory anemia with excess blast (RAEB), RAEB in transformation (RAEBt), or AML following MDS (these categories are defi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ee72795767440619d1b6e8c116069e
https://doi.org/10.1038/sj.leu.2404136
https://doi.org/10.1038/sj.leu.2404136